Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.Andrew M. Evens, Nancy L. Bartlett, Sriram Balasubramanian et al.|Blood|2009Cited by 8